MDS O is a medication used primarily in the management of blood disorders such as myelodysplastic syndromes (MDS). It contains Azacitidine, a chemotherapy agent that works by interfering with the growth of abnormal cells in the bone marrow, allowing normal blood cell production. Azacitidine belongs to a class of drugs called antimetabolites. It incorporates into the DNA and RNA of abnormal cells, inhibiting their replication and promoting the restoration of normal bone marrow function.

Indications: MDS O is prescribed for-

• Myelodysplastic Syndromes (MDS)
• Chronic Myelomonocytic Leukemia (CMML)
• Acute Myeloid Leukemia (AML) in certain cases
• Treatment of other marrow-related abnormalities as determined by a healthcare provider